Regulation of TERRA on telomeric and mitochondrial functions in IPF pathogenesis
Male
0301 basic medicine
Aging
Apoptosis
Diseases of the respiratory system
Mice
03 medical and health sciences
lncRNA
Animals
Humans
Aged
Cell Proliferation
RC705-779
Superoxide Dismutase
TERRA
Hydrogen Peroxide
Telomere
Middle Aged
Catalase
Idiopathic Pulmonary Fibrosis
Mitochondria
3. Good health
IPF
A549 Cells
Case-Control Studies
Female
RNA Interference
RNA, Long Noncoding
Reactive Oxygen Species
Research Article
DOI:
10.1186/s12890-017-0516-1
Publication Date:
2017-12-02T03:51:03Z
AUTHORS (10)
ABSTRACT
Aging is a known risk factor of idiopathic pulmonary fibrosis (IPF). However, the pathogenic mechanisms underlying effects advanced aging remain largely unknown. Telomeric repeat-containing RNA (TERRA) represents type long noncoding RNA. In this study, regulatory roles TERRA on human telomeres and mitochondria IPF epithelial injury model were identified. Blood samples collected from patients with (n = 24) matched control individuals 24). The significance clinical research expression correlated was assessed. levels in vivo vitro determined through quantitative real-time polymerase chain reaction analysis. Telomerase activity observed using fluorescent TRAP assay kit. functions telomeres, mitochondria, associated genes analyzed interference TERRA. significantly increased peripheral blood mononuclear cells patients. also exhibited direct inverse correlation percentage predicted force vital capacity, which physiological indicator fibrogenesis during progression. This finding confirmed vitro. can ameliorate telomeres; mitochondria; genes; components such as telomerase reverse transcriptase, telomerase, cell nuclear antigen, cyclin D1; mitochondria-associated E genes, including MMP Bcl-2 family. improve oxidative-stress-associated reactive oxygen species, superoxide dismutase, catalase, apoptosis-related cytochrome c, caspase-9, caspase-3. regulation pathogenesis identified for first time. results may provide valuable insights discovery novel biomarker or therapeutic approach treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (49)
CITATIONS (34)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....